CA3237696A1 — Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
Assigned to Progentos Therapeutics Inc · Expires 2023-05-11 · 3y expired
What this patent protects
The present disclosure provides compounds that can specifically target a PDGFR?, and thereby, reduce and/or inhibit the activation of the receptor ("PDGFR? inhibitor"). The present disclosure also provides methods of treating a demyelinating disease using the disclosed PD…
USPTO Abstract
The present disclosure provides compounds that can specifically target a PDGFR?, and thereby, reduce and/or inhibit the activation of the receptor ("PDGFR? inhibitor"). The present disclosure also provides methods of treating a demyelinating disease using the disclosed PDGFR? inhibitors.
Drugs covered by this patent
- Ayvakit (AVAPRITINIB) · Blueprint Medicines
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.